Latest Trends in Respiratory Medicine: Promising Solutions for Lung Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 1443

Special Issue Editor

Special Issue Information

Dear Colleagues,

This special issue focuses on the latest advancements in respiratory medicine, with a particular emphasis on the development of promising solutions for lung diseases. The field of respiratory medicine has witnessed significant progress in recent years, as researchers and clinicians continue to explore innovative approaches to diagnosis, treatment, and prevention.

The articles in this special issue cover a wide range of topics, including cutting-edge diagnostic techniques such as molecular biomarkers and imaging technologies that enable early detection and accurate diagnosis of lung diseases. Additionally, novel therapeutic interventions are highlighted, including personalized medicine approaches that take into account individual characteristics and genetic factors to tailor treatment plans.

Overall, this special issue provides a comprehensive overview of the latest trends in respiratory medicine, highlighting the potential of promising solutions to revolutionize the field and improve patient outcomes. For this Special Issue, we welcome all perspectives and high-quality research articles, including but not limited to original research articles and review articles.

Dr. I-Shiang Tzeng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • biomarker
  • chronic obstructive pulmonary disease
  • pulmonary fibrosis
  • respiratory
  • diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 724 KiB  
Review
Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
by Fabio Perrotta, Stefano Sanduzzi Zamparelli, Vito D’Agnano, Antonia Montella, Ramona Fomez, Raffaella Pagliaro, Angela Schiattarella, Mario Cazzola, Andrea Bianco and Domenica Francesca Mariniello
Biomedicines 2024, 12(7), 1384; https://doi.org/10.3390/biomedicines12071384 - 21 Jun 2024
Viewed by 1130
Abstract
Idiopathic pulmonary fibrosis (IPF) has traditionally been considered the archetype of progressive fibrotic interstitial lung diseases (f-ILDs), but several other f-ILDs can also manifest a progressive phenotype. Integrating genomic signatures into clinical practice for f-ILD patients may help to identify patients predisposed to [...] Read more.
Idiopathic pulmonary fibrosis (IPF) has traditionally been considered the archetype of progressive fibrotic interstitial lung diseases (f-ILDs), but several other f-ILDs can also manifest a progressive phenotype. Integrating genomic signatures into clinical practice for f-ILD patients may help to identify patients predisposed to a progressive phenotype. In addition to the risk of progressive pulmonary fibrosis, there is a growing body of literature examining how pharmacogenomics influences treatment response, particularly regarding the efficacy and safety profiles of antifibrotic and immunomodulatory agents. In this narrative review, we discuss current studies in IPF and other forms of pulmonary fibrosis, including systemic autoimmune disorders associated ILDs, sarcoidosis and hypersensitivity pneumonitis. We also provide insights into the future direction of research in this complex field. Full article
Show Figures

Figure 1

Back to TopTop